26Feb 2020

PSORIASIS AND PREGNANCY CHALLENGES AND RISKS

  • MBChB, FICMS Dermatology, Dermatological Department Alkhadumyia Teaching Hospital.
  • MBChB, CABOG Specialist In Obstetric And Gynecology.
  • MBChB, HD Specialist In Orthopaedics And Rheumatology.
Crossref Cited-by Linking logo
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author
  1. Liu Y, Krueger JG, Bowcock AM. Psoriasis: genetic associations and immune system changes. Genes and Immunity 2007:8;1-12.
  2. A. Johnson and A. W. Armstrong, ?Clinical and histologic diagnostic guidelines for psoriasis: a critical review,? Clinical Reviews in Allergy Immunology, vol. 44, 2, pp. 166?172, 2013.
  3. Levine D, Gottlieb A. Evaluation and management of psoriasis: An internist?s guide. Med Clin North Am. 2009;93: 1291-303.
  4. Busch AL, Landau JM, Moody MN. Pediatric psoriasis. Skin Ther Lett. 2012;17:5-7.).
  5. T. Islam, H. K. Paul, S. M. Zakaria, M. M. Islam, and M. Shafiquzzaman, ?Epidemiological determinants of psoriasis,? Mymensingh Medical Journal, vol. 20, no. 1, pp. 9?15, 2011.)
  6. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemi- ology of psoriasis: a systematic review of incidence andprevalence. J Invest Dermatol 2013; 133:377?85.).
  7. Tauscher AE, Fleischer AB, Phelps KC, Feldman SR. Psoriasis and pregnancy. J Cutan Med Surg 2002;6:561?70.).
  8. Tauscher AE, Fleischer AB Jr, Phelps KC, Feldman SR. Psoriasis and pregnancy. J Acta Dermatovenerol Croat 2009;17(3):193-197Cutan Med Surg 2002;6:561-70.).
  9. Gupta and A. Gupta, ?Psychological factors and psoriasis,? in Epidemiology, Causes and Prevention of Skin Diseases, J. J. Grob, R. Stern, R. Mackie, and W. Weinstock, Eds., pp. 129?141, Blackwell Science, Oxford, UK, 1997.)
  10. National Psoriasis Foundation. Spring 2005: Survey panelsnapshot.http://www.psoriasis.org/document.doc?id=377. Accessed February 4, 2014.).
  11. Weatherhead S, Robson SC, Reynolds NJ. Management of psoriasis in pregnancy. BMJ 2007; 334:1218?20.).
  12. Doria A, Iaccarino L, Arienti S, Ghirardello A, Zampieri S, Rampudda ME, et al. Th2 immune deviation induced by pregnancy: The two faces of autoimmune rheumatic diseases. ReprodToxicol. 2006;22:234-41.).
  13. Murase J, Chan KK, Garite TJ, Cooper DM, Weinstein GD. Hor- monal effect on psoriasis in pregnancy and post partum. Arch Dermatol. 2005;141:601-6.
  14. Shigeru S. Cytokine cross-talk between mother and the embryo/placenta. J ReprodImmunol. 2001;52: 15-33.).
  15. Bandoli G, Johnson DL, Jones KL, Lopez Jimenez J, Salas E, Mirrasoul N, et al. Potentially modifiable risk factors for adverse pregnancy outcomes in women with psoriasis. Br J Dermatol. 2010;163:334-9.)
  16. Raychaudhuri SP, Navare T, Gross J, Raychaudhuri SK. Clin- ical course of psoriasis during pregnancy. Int J Dermatol. 2003;42:518-20.).
  17. Lima X, Janakiraman V, Hughes M, Kimball A. The impact of psoriasis on pregnancy outcomes. J Invest Dermatol. 2012;132:85-91.).
  18. Ruiz V, Manubens E, Puig L. Psoriasis in pregnancy: A review (I). Actas Dermosifiliogr 2014;105:734?43.).
  19. Coimbra, A. Figueiredo, E. Castro, P. Rocha-Pereira, and A. Santos-Silva, ?The roles of cells and cytokines in the pathogenesis of psoriasis,? International Journal of Dermatology, vol. 51, no. 4, pp. 389?398, 2012.).
  20. Pietrzak, B. Lecewicz-Torun ́, and A. Jakimiuk, ?Lipid and hormone profile in psoriatic females,? AnnalesUniversitatisMariaeCurie-Skłodowska. Sectio D, vol. 57, no. 2, pp. 478?483, 2002.).
  21. Kanda and S. Watanabe, ?Regulatory roles of sex hormones in cutaneous biology and immunology,? Journal of Dermatological Science, vol. 38, no. 1, pp. 1?7, 2005.).
  22. M. Pennell, C. L. Galligan, and E. N. Fish, ?Sex affects immunity,? Journal of Autoimmunity, vol. 38, no. 2-3, pp. J282? J291, 2012.).
  23. L. Landau, M. N. Moody, N. Kazakevich, and L. H. Goldberg, ?Psoriasis and the pregnant woman: what are the key consider- ations?? Skin Therapy Letter, vol. 16, no. 9, pp. 1?3, 2011.).
  24. Engineer L, Bhol K, Ahmed AR. Pemphigoid gestationis: A review. Am J ObstetGynecol.2000;183:483-91.).
  25. Barankin B, Silver SG, Carruthers A. The skin in pregnancy. J Cutan Med Surg. 2002;6:236-40.)
  26. Shelly, M. Boaz, and H. Orbach, ?Prolactin and autoimmunity,? Autoimmunity Reviews, vol. 11, no. 6-7, pp.A465?A470, 2012.)
  27. S. Dhabhar, ?Psychological stress and immunoprotection versus immunopathology in the skin.,? Clinics in Dermatology, vol. 31, no. 1, pp. 18?30, 2013 ).
  28. M. Mowad, D. J. Margolis, A. C. Halpern, B. Suri, M. Synnestvedt, and C. A. Guzzo, ?Hormonal influences on women with psoriasis,? Cutis, vol. 61, no. 5, pp. 257?260, 1999.
  29. S. Boyd, L. F. Morris, C. M. Phillips, and M. A. Menter, ?Psoriasis and pregnancy: hormone and immune system interaction,? International Journal of Dermatology, vol. 35, no. 3, pp. 169?172, 1996.
  30. [ R. Ceovic, J. Lipozencic, A. Pasic, and K. Kostovic, ?Psoriasis in pregnancy: a review of most important literature data,? Acta DermatovenerologicaCroatica, vol. 17, no. 3, pp. 193?197, 2009.])
  31. Carlsten, N. Nilsson, R. Jonsson, K. Backman, R. Holmdahl, and A. Tarkowski, ?Estrogen accelerates immune complex glomerulonephritis but ameliorates T cell-mediated vasculitis and sialadenitis in autoimmune MRL lpr/lpr mice,? Cellular Immunology, vol. 144, no. 1, pp. 190?202, 1992.)
  32. E. Murase, K. K. Chan, T. J. Garite, D. M. Cooper, and G. D. Weinstein, ?Hormonal effect on psoriasis in pregnancy and post partum,? Archives of Dermatology, vol. 141, no. 5, pp. 601?606, 2005).
  33. Weatherhead,S.C.Robson,andN.J.Reynolds,?Managementof psoriasis in pregnancy,? British Medical Journal, vol. 334,no.7605, pp. 1218?1220, 2007.).
  34. Kar, A. Krishnan, and P. V. Shivkumar, ?Pregnancy and skin,?The Journal of Obstetrics and Gynecology of India, vol. 62, no. 3,pp. 268?275, 2012.).
  35. Murase JE, Heller MH, Butler DC. Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy. J Am Acad Dermatol 2014; 70:401.e1?14.).
  36. S. C. Bae, A. S. Van Voorhees, S. Hsu et al., ?Review oftreatment options for psoriasis in pregnant or lactating women: from the medical board of the national psoriasis foundation,? Journal of the American Academy of Dermatology, vol. 67, no. 3, pp. 459?477, 2012.
  37. Weatherhead S, Robson SC, Reynolds N. Management of psoriasis in pregnancy. BMJ 2007;334:1218-20.)
  38. Lam J, Polifka JE, Dohil AM. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol 2008;59:295- 315.
  39. Tyler KH, Zirwas MJ. Pregnancy and dermatologic therapy. J Am Acad Dermatol. 2013;68(4):663?671. [PubM].
  40. Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol. 1.2014;70(3):401.e1-e14. [PubMed].
  41. Morra P, Bartle WR, Walker SE, Lee SN, Bowles SK, Reeves RA. Serum concentrations of salicylic acid following topically app- lied salicylate derivatives. Ann Pharmacother 1996;30:935-40.
  42. Torloni MR, Cordioli E, Zamith MM, Hisaba WJ, Nardozza LM, Santana RM, et al. Reversible constriction of the fetal ductus arteriosus after maternal use of topical diclofenac and methyl salicylate. Ultrasound ObstetGynecol. 2006;27: 227-9.
  43. Tauscher AE, Fleischer AB Jr, Phelps KC, Feldman SR. Psoriasis and pregnancy. JActa Dermatovenerol Croat 2009;17(3):193-197
  44. Cutan Med Surg 2002;6:561-70.
  45. Koo YM. Current consensus and update on psoriasis therapy: a perspective from the Uni- ted States. J Dermatol 1999;26:723-33.
  46. Dovonex label (Brystol-Myers Squibb). [accessed 6 Jun 2013]. Available in: http://dailymed.nlm.nih.gov/dailymed/ lookup.cfm?setid=13916cd3-6fe6-401e-af71-07ae2686bce0.
  47. Soter NA, Fleischer AB, Webster GF. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, Safety. J Am Acad Dermatol 2001;44:S39-S46.
  48. Bridges BA. An estimate of genetic risk from 8-methoxypsoralenphotochemotherapy. Hum Genet 1979;49:91-6.
  49. Franssen ME, van der Wilt GJ, de Jong PC, Bos RP, Arnold WP. A retrospective study of the teratogenicity of dermatological coal tar products. Acta DermVenereol. 1999;79(5):390?391
  50. Armenti VT, McGrory CH, Cater JR, Radomski JS, Moritz MJ. Pregnancy outcomes in female transplant recipients. Transplant Proc.
  51. 1998;30(5):1732?1734. [PubMed] [Google Scholar].
  52. Spuls PI, Bossuyt PM, van Everdingen JJ. The development of practice guidelines for the treatment of severe plaque-form psoriasis. Arch Dermatol 1998;134:1591-6.
  53. Stern RS, Lange R. Outcomes of pregnancies among women and partners of men with a history of exposure to methoxsalen- photochemotherapy (PUVA) for the treatment of psoriasis. Arch Dermatol. 1991;127(3):347?350.
  54. Gunnarskog JG, Källén AJ, Lindelöf BG, Sigurgeirsson B. Psoralen photochemotherapy (PUVA) and pregnancy. Arch Dermatol.
  55. Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT. Retinoic acid embryopathy. N Engl J Med 1985;313:837-41.
  56. Kozlowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, Segal AM.Outcome of first-trimester exposure to low-dose methotrexate in eight patientswith rheumatic disease. Am J Med. 1990;88:589-92.
  57. Lam J, Polifka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. JAm Acad Dermatol. 2008;59(2):295?315.
  58. Perales-Puchalt A, Vila Vives JM, Lopez Montes J, DiagoAlmela VJ, Perales AJ. Pregnancy outcomes after kidneytransplantation-immunosuppressive therapycomparison. Matern Fetal Neonatal Med. 2012;25:1363-6.
  59. Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporinetherapy during pregnancy: a meta-analysis. Transplantation. 2001;71:1051-5.
  60. Moretti ME, Sgro M, Johnson DW, Sauve RS, Woolgar MJ, Taddio A, et al. Cyclosporine excretion into breast milk.Transplantation. 2003;75:2144-6.
  61. Chambers CD, Johnson DL. Emerging data on the use of anti-tumor necrosis factor- alpha medications in pregnancy. Birth Defects Res A Clin Mol Teratol 2012;94: 607?11.
  62. Förger F, Villiger PM. Treatment of rheumatoid arthritis during pregnancy: Present and future. Expert Rev Clin Immunol 2016;12:937?44.
  63. Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case report: Fatal case of dissemi- nated BCG infection in an infant born to a mother taking infliximab for Crohn\'s disease. J Crohns Colitis 2010;4:603?5.
  64. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome ofpregnancy in women receiving infliximab for the treatment of Crohn?s diseaseand rheumatoid arthritis. Am J Gastroenterol. 2004;99:2385-92.
  65. Johnson DL, et al. Pregnancy outcomes in women exposed to etanercept: the OTIS Autoimme Diseases in Pregnancy Project. Arthritis Rheum. 2008;58:Abstract 1387.
  66. Chambers CD, et al. Pregnancy outcomes in women exposed to adalimum- ab for the treatment of rheumatoid arthritis.Pharmacoepidemiol Drug Saf. 2012;21(Suppl 3):377.
  67. Andrulonis R, Ferris LK. Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol 2012;11:1240-1.
  68. Ben-Horin S, Yavzori M, Katz L, Picard O, Fudim E, Chowers Y, et al. Adalimumab level in breast milk of a nursing mother. ClinGastroenterol Hepatol. 2010;8:475-matory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286-92. 6.
  69. Yiu, Z.Z.; Griffiths, C.E.; Warren, R.B. Safety of biological therapies for psoriasis: Effects on reproductive potential and outcomes in male and female patients. Br. J. Dermatol. 2014, 171, 485?491.

[Soad S. Jabor, Huda Salim Al-Habeeb and Nibras S. Khadum (2020); PSORIASIS AND PREGNANCY CHALLENGES AND RISKS Int. J. of Adv. Res. 8 (2). 242-248] (ISSN 2320-5407). www.journalijar.com


Soad salman
Dermatologist

DOI:


Article DOI: 10.21474/IJAR01/10459       DOI URL: http://dx.doi.org/10.21474/IJAR01/10459


Share this article